September 6, 2012
Makoto Naiki, Senior Marketing Director, Primary Care Bolstered by the recent approval for an additional indication for its asthma and chronic obstructive pulmonary disease (COPD) treatment Symbicort (budesonide + formoterol), AstraZeneca K.K. (AZ) is aiming for the top market share...read more